These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22199335)

  • 1. Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
    Tanaka Y; Yoshida K; Osada S; Yamaguchi K; Takahashi T
    Anticancer Res; 2011 Dec; 31(12):4589-97. PubMed ID: 22199335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K
    Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
    Miyazaki A; Kobayashi J; Yamamoto T; Kido Y; Takemura K; Abe M; Tomihara K; Dehari H; Nakamori K; Nagai I; Hiratsuka H
    Oral Oncol; 2008 May; 44(5):471-6. PubMed ID: 17826308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
    Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
    Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of nedaplatin prior to S-1 in patients with locally advanced head and neck squamous cell carcinoma.
    Sato D; Kogashiwa Y; Tsukahara K; Yamauchi K; Kohno N
    Chemotherapy; 2013; 59(4):314-8. PubMed ID: 24480865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study of docetaxel with a fixed dose of S-1 in combination chemotherapy for advanced gastric cancer.
    Kim YH; Seo HY; Jeen YT; Kim HK; Shim BY; Yang J
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):253-60. PubMed ID: 18493761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer.
    Hayashi H; Okamoto I; Ueda S; Tanaka K; Okamoto K; Kawakami H; Nishina S; Takeda M; Fujisaka Y; Satoh T; Terao K; Nishimura Y; Doi K; Nakagawa K
    Anticancer Res; 2013 Dec; 33(12):5699-705. PubMed ID: 24324120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
    Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
    Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
    Yoshioka T; Sakayori M; Kato S; Chiba N; Miyazaki S; Nemoto K; Shibata H; Shimodaira H; Ohtsuka K; Kakudo Y; Sakata Y; Ishioka C
    Int J Clin Oncol; 2006 Dec; 11(6):454-60. PubMed ID: 17180514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
    Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
    Hirao M; Fujitani K; Tsujinaka T
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):53-6. PubMed ID: 15675582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
    Fan QX; Wang R; Lu P; Zhao YF; Lu TY; Han JW; Wang JS; Luo SX; Lu SP; Wang GJ; Geng L; Zhang MZ; Ma ZY; Song M; Wu XA; Chen XB; Jiao ZM; Wang RL
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):937-9. PubMed ID: 19173998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer.
    Kodaira T; Fuwa N; Tachibana H; Hidano S
    Anticancer Res; 2006; 26(3B):2265-8. PubMed ID: 16821599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
    Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
    Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
    Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
    Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma.
    Kodaira T; Fuwa N; Kamata M; Furutani K; Tachibana H; Yamazaki T
    Anticancer Res; 2006; 26(1B):471-8. PubMed ID: 16739307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer.
    Zang DY; Yang DH; Kim MJ; Jang KM; Hwang SW; Yoo KS; Han T; Kim HY; Kim HJ; Kwon JH; Song HH; Park S; Jung JY; Kim HS; Kim JH
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):877-83. PubMed ID: 19190908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.